- Home
- MCRB vs GHI Comparison
MCRB vs GHI Comparison
Compare MCRB & GHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCRB | GHI |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 161.5M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | MCRB | GHI |
|---|---|---|
| Price | $15.04 | $7.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $14.33 | $13.00 |
| AVG Volume (30 Days) | 43.7K | ★ 98.6K |
| Earning Date | 03-12-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 18.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.62 | 0.17 |
| Revenue | $351,000.00 | ★ $26,247,399.00 |
| Revenue This Year | N/A | $201.02 |
| Revenue Next Year | N/A | $2.87 |
| P/E Ratio | ★ $24.47 | $47.01 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.53 | $6.01 |
| 52 Week High | $29.98 | $13.29 |
Technical Indicators
Market Signals| Indicator | MCRB | GHI |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 53.06 |
| Support Level | $14.41 | $7.66 |
| Resistance Level | $16.12 | $8.04 |
| Average True Range (ATR) | 0.83 | 0.33 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 44.28 | 52.19 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.